LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

NCT02159066 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: LGX818
DRUG: MEK162
DRUG: LEE011
DRUG: BGJ398
DRUG: BKM120
DRUG: INC280

Sponsor

Pfizer